Contact
Please use this form to send email to PR contact of this press release:
RESULTS FROM THE PHASE III HERCULES STUDY OF CAPLACIZUMAB FOR THE TREATMENT OF ACQUIRED TTP SELECTED FOR PRESENTATION IN THE LATE-BREAKING ABSTRACTS SESSION AT THE 2017 ASH ANNUAL MEETING
TO: